Skip to main content

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update

Resverlogix Corp

4820 Richard Road South West
Suite 300
Calgary AB T3E 6L1 CAN
P: 403-254-9252
F: 403-256-8495
https://www.resverlogix.com

Sectors & Indices

Sector
Industry
Employees

    Profile

    Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

    Key Executives

    NameTitle
    Michael SweeneySenior VP, Divisional
    A. Brad CannCFO
    Donald J. McCaffreyCEO/Co-Founder/Director/President/Secretary/Chairman of the Board
    Ewelina KulikowskiChief Scientific Officer/Senior VP, Divisional

    More from The Globe